SG Americas Securities LLC Purchases 11,539 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

SG Americas Securities LLC raised its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 455.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,070 shares of the company’s stock after acquiring an additional 11,539 shares during the period. SG Americas Securities LLC’s holdings in Editas Medicine were worth $578,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Editas Medicine by 2.1% in the second quarter. Vanguard Group Inc. now owns 6,483,932 shares of the company’s stock valued at $367,250,000 after buying an additional 136,178 shares during the period. State Street Corp lifted its stake in shares of Editas Medicine by 9.1% in the second quarter. State Street Corp now owns 2,534,162 shares of the company’s stock valued at $143,535,000 after buying an additional 210,444 shares during the period. Geode Capital Management LLC lifted its stake in shares of Editas Medicine by 4.5% in the second quarter. Geode Capital Management LLC now owns 1,205,271 shares of the company’s stock valued at $68,266,000 after buying an additional 51,906 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Editas Medicine by 17.0% in the second quarter. JPMorgan Chase & Co. now owns 1,102,447 shares of the company’s stock valued at $62,443,000 after buying an additional 160,178 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Editas Medicine by 133.8% in the second quarter. Dimensional Fund Advisors LP now owns 629,031 shares of the company’s stock valued at $35,605,000 after buying an additional 360,003 shares during the period. Institutional investors own 75.93% of the company’s stock.

In other news, CEO James C. Mullen sold 13,805 shares of the firm’s stock in a transaction on Monday, October 18th. The stock was sold at an average price of $38.03, for a total value of $525,004.15. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Michelle Robertson sold 1,744 shares of the stock in a transaction dated Tuesday, January 11th. The shares were sold at an average price of $25.70, for a total value of $44,820.80. The disclosure for this sale can be found here. Insiders have sold 17,404 shares of company stock worth $641,581 over the last three months. 0.94% of the stock is owned by insiders.

NASDAQ EDIT opened at $22.10 on Friday. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -6.82 and a beta of 1.93. The company has a 50 day moving average of $30.51 and a 200-day moving average of $43.37. Editas Medicine, Inc. has a 1-year low of $20.90 and a 1-year high of $83.95.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Monday, November 8th. The company reported ($0.57) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.24. Editas Medicine had a negative net margin of 871.91% and a negative return on equity of 38.28%. The business had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $4.92 million. During the same period in the prior year, the firm earned $0.12 earnings per share. Editas Medicine’s revenue was down 90.1% compared to the same quarter last year. Research analysts expect that Editas Medicine, Inc. will post -3.16 earnings per share for the current year.

Several research firms recently weighed in on EDIT. Morgan Stanley reduced their target price on shares of Editas Medicine from $37.00 to $24.00 and set an “underweight” rating for the company in a research note on Thursday, January 6th. Stifel Nicolaus dropped their price target on shares of Editas Medicine from $65.00 to $46.00 and set a “hold” rating for the company in a research report on Thursday, September 30th. Chardan Capital reissued a “buy” rating and issued a $75.00 price target on shares of Editas Medicine in a research report on Thursday, September 30th. SVB Leerink started coverage on shares of Editas Medicine in a research report on Tuesday, October 19th. They issued a “market perform” rating and a $41.00 price target for the company. Finally, Robert W. Baird reissued a “buy” rating on shares of Editas Medicine in a research report on Wednesday, October 20th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Editas Medicine has a consensus rating of “Hold” and an average price target of $54.29.

About Editas Medicine

Editas Medicine, Inc engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.

Recommended Story: What is a put option?

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.